Previous studies suggest that APOE4 carrier status is associated with a higher risk of AD through both amyloid- and tau-dependent and independent pathways, such as increasing neuroinflammation, disrupting glucose and lipid metabolism, and reducing neurovascular integrity (Yamazaki et al., 2019). Here, MAPT is linked to Alzheimer disease.